Diagnostic Imaging's A Look Ahead: Feb. 1, 2021, to Feb. 5, 2021


Here's what to expect this week on Diagnostic Imaging.

In this week’s preview, here are some highlights of what you can expect to see coming soon:

The COVID-19 pandemic has made already difficult purchasing decisions even harder for many organizations. Is it possible for organizations to hit the sweet spot in investing in new technologies and controlling costs? This week, Guido Stoeckmann, regional sales manager for Dunlee, a medical imaging components manufacturer, offers guidance on how you can – and should – re-define your imaging technology investments. Look for his column later this week.

For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.

Recent conversations around low-dose CT screening for lung cancer have pointed out its low participation rates and discussed its efficacy. This week, however, in research presented at the 2021 World Conference on Lung Cancer, investigators from Taiwan are sharing their results on the performance of the screening in a never-smoker population. Look for our coverage of their encouraging results later this week.

For additional low-dose CT screening coverage, click here.

Treatments for prostate cancer, such as surgery or radiation therapy, are effective, but they often bring unwanted side effects. This week, in Radiology, investigators will share the outcomes of their work with a different technique that can be used to treat intermediate-risk prostate cancer. Keep your eyes open for details about their study.

For additional coverage of prostate cancer, click here.

Related Videos
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2023 MJH Life Sciences

All rights reserved.